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Abstract. Background: Arterial stiffness 
and low heart rate variability (HRV) have 
each been associated with increased cardio-
vascular risk in a variety of patient popula-
tions. We explored the relationship between 
HRV and pulse wave velocity (PWV measure 
of arterial stiffness) in patients with chronic 
kidney disease (CKD prior to ESRD) along 
with examining their association with the 
outcomes of cardiovascular disease (CVD), 
death, and progression to end stage renal 
disease (ESRD). Methods: The RRI-CKD 
Study is a 4-center prospective cohort study 
of CKD stages 3 – 5 (n = 834). A subset un-
derwent both HRV testing by 24-hour Holter 
and carotid-femoral PWV (n = 240). Mul-
tiple linear regression was used to assess 
predictors of PWV and Cox regression to 
investigate the association of HRV and PWV 
with time to first CVD event or death and 
ESRD. Results: Although several HRV mea-
sures were inversely correlated with PWV, 
this association was attenuated after adjust-
ment for age and/or diabetes and no longer 
significant after adjustment for C-reactive 
protein. Low HRV and high PWV were indi-
vidually associated with increased risk of the 
composite endpoint of CVD/death in multi-
variable analysis. The risk of the composite 
of CVD/death was highest for patients with 
both low HRV and high PWV. Conclusion: 
Age, diabetes, and inflammation together ex-
plained the inverse association between HRV 
and PWV. Inflammation may play a role in 
the pathogenesis of both low HRV and high 
PWV. The combination of low HRV and high 
PWV showed the strongest association with 
a composite CVD outcome. Mechanisms 
underlying abnormalities in PWV and HRV, 
and the role of these measures as intermedi-
ate outcomes in future trials in CKD patients, 
merit further study.
Introduction
Arterial stiffness as measured by pulse 
wave velocity (PWV) is associated with in-
creased risk of cardiovascular disease (CVD) 
and overall mortality both in patients with 
hypertension and those with end stage re-
nal disease (ESRD) on dialysis [1, 2, 3, 4]. 
Several factors such as higher blood pressure 
(BP), dyslipidemia, diabetes mellitus, in-
flammation, and calcification, among others 
could underlie the pathogenesis of a higher 
PWV in chronic kidney disease (CKD) [4, 
5]. Higher PWV has also been linked with 
lower kidney function in many though not 
all studies [6, 7, 8]. CKD is associated with 
altered autonomic regulation with increased 
sympathetic activity [9]. Autonomic dys-
function as measured by low heart rate vari-
ability (HRV) is associated with increased 
cardiovascular and overall mortality in dia-
betics, CVD, and patients with kidney dis-
ease [10, 11]. Autonomic dysfunction has 
been shown to be inversely related to PWV 
in patients with diabetes [12, 13, 14, 15] and 
also in patients on dialysis [16], but there is 
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only limited data on the non-dialysis CKD 
population [17].
We postulated that autonomic dysfunc-
tion (increased sympathetic activity, in par-
ticular) in those with CKD would be asso-
ciated with increased arterial stiffness. We 
additionally sought to examine the combined 
risk posed by alterations in HRV and PWV 
in predicting the composite of CVD and/or 
death and ESRD outcomes in a CKD cohort.
Methods
The Renal Research Institute (RRI)-CKD 
Study is a 4-center, prospective cohort study 
of adults with moderate-to-severe CKD 
(stages 3 – 5) enrolled between June 2000 
and February 2006 (n = 834). The study 
methodology has been published previously 
[18]. Briefly, eligibility criteria included age 
≥ 18 years and estimated glomerular filtra-
tion rate (eGFR) ≤ 50 mL/min by the Cock-
roft-Gault formula. Subsequently, the ab-
breviated (4-variable) Modification of Diet 
in Renal Disease (MDRD) equation was 
used and eGFR was between 50 and 60 mL/
min/1.73m2 in 14 subjects. To exclude pa-
tients with transient renal impairment prior 
to enrollment, GFR was estimated on two 
occasions at least 1 month apart. At enroll-
ment and follow-up visits, data on demo-
graphic characteristics, anthropometric mea-
sures, cause of CKD, symptoms, laboratory 
values, and medication data were collected. 
From January 1, 2003 onwards, individuals 
from the original RRI-CKD cohort (n = 627) 
were invited to undergo non-invasive cardio-
vascular studies, including pulse wave veloc-
ity and 24-hour Holter monitoring as part of 
a cardiovascular (CV) sub-study.
Figure 1 displays patient recruitment flow 
into this CV sub-study. Patients who consent-
ed into the new CV sub-study from the origi-
nal RRI-CKD study (n = 149) were generally 
healthier than those who did not; they were 
younger (mean age 58 vs. 64), had higher 
mean eGFR (27 vs. 25), and fewer had dia-
betes (30% vs. 42%) or history of CVD (37% 
vs. 58%). However, the 199 newly recruited 
patients into the CVD sub-study – while 
similar to these original RRI-CKD cohort 
participants with respect to age, diabetes, 
hypertension, history of CVD, race, gen-
der, and medication use – had significantly 
higher mean eGFR (32 vs. 24). The differ-
ence between the CV sub-study and original 
RRI-CKD participants was due to patient 
self-selection into a study that involved sub-
stantial testing and patient burden. This se-
lection seems especially likely because the 
characteristics of the newly recruited CV 
sub-study patients were similar to the con-
senters from the original RRI-CKD cohort. 
Finally, of the 348 patients who entered into 
the CV sub-study, 43 declined Holter moni-
toring. These patients were otherwise similar 
to the 305 who underwent this procedure, 
except for significantly older mean age (67 
vs. 60). There were no significant differenc-
es between patients who underwent PWV 
measurement and and those who declined 
(n = 74). The present analysis includes the 
240 patients who underwent both HRV and 
PWV measurements.
Study coordinators at each site were 
trained in Holter monitoring and other study 
procedures at the University of Michigan 
Data Coordinating Center (DCC) to ensure 
uniformity of technique across centers. Dur-
ing the 24-hour Holter, patients went about 
their usual activities but were asked to refrain 
from heavy physical activity. The Holter 
data were transferred electronically via a file 
transfer protocol (FTP) to the DCC where 
they were analyzed using SyneTec Holter 
analysis software, version 1.20 (Ela Medical, 
Paris, France) under the supervision of the 
Figure 1. Patient recruitment flow into the cardio-
vascular sub-study of the RRI-CKD study (n = 305).
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study cardiologist (SR). The 24-hour trac-
ing was examined, and masking was used 
to exclude areas of artifact. Abnormal atrial 
and ventricular rhythms were manually veri-
fied. Time and frequency domain measures 
were calculated for the 24-hour period, day 
(8:00 AM – 9:00 PM) and night periods. Pa-
tients on nitroglycerin patch, with defibrilla-
tor, active pacing, or with allergy to electrode 
adhesive material were excluded. The termi-
nology/abbreviations pertaining to the HRV 
parameters collected in this study are shown 
in Table S1.
“Central” arterial stiffness was assessed 
using carotid-femoral PWV. Systolic and 
diastolic blood pressures (SBP, DBP) were 
measured after a 5-minute rest in the supine 
position. The length of the descending aorta 
was approximated by subtracting the manu-
brium-carotid distance from the manubrium-
femoral artery distance. A hand-held tonom-
eter was placed over the carotid and then 
femoral arteries to record pressure waves. 
Simultaneous EKG tracings were recorded. 
PWV was calculated in an automated fash-
ion (AtCor version 7.0). Four measurements 
were recorded for each subject. A measure-
ment was excluded if the pressure contour 
was of poor quality or a > 15% difference in 
heart rate (HR) was found between the ca-
rotid and femoral measurements. A subject’s 
PWV was the average of the acceptable mea-
surements.
The outcomes studied were the compos-
ite of CVD/Death and ESRD. CVD events 
included those related to coronary artery 
disease (CAD), cerebrovascular disease, 
peripheral arterial disease, congestive heart 
failure (CHF), and cardiac arrest. ESRD was 
defined by documented initiation of dialysis 
or preemptive renal transplantation. All out-
comes were ascertained on an ongoing basis 
by study coordinators through regular re-
view of electronic health records, direct pa-
tient contact in clinic, and periodic telephone 
communication. CVD events to be collected 
were pre-specified and identified using a 
CVD event data collection form. Follow-up 
of patients ended on December 31, 2006. 
Study protocol was approved at all sites by 
their individual Institutional Review Boards. 
All subjects provided written informed con-
sent.
Statistical Analysis
Multivariable regression models were 
used to explore the association between 
HRV and PWV after simultaneous adjust-
ment for variables associated with PWV in 
Table 1. Patients characteristics at the time of non-invasive cardiovascular 
testing in the RRI-chronic kidney disease (CKD) cohort (n = 240a).
Variable Mean (SD) or median 
(min, max) or % (n)
Demographics/anthropometrics 
Age 60 (15)
Body mass index (kg/m2) 28.6 (5.9)
Gender: male 53% (128)
Race: white 78% (187)
Race: black 18% (43)
Race: other 4% (10)
Current/former smoker 47% (113)
Cardiovascular Indices
 Total cholesterol (mg/dL) 92 ± 54
 Systolic blood pressure (mm/Hg) 139 ± 23
 Diastolic blood pressure (mm/Hg) 78 ± 13
Comorbidities
 Diabetes 30% (72)
 Hypertension 89% (214)
 Cardiovascular disease 35% (85)
Cause of CKDb
 Diabetes 25% (59)
 Hypertension 51% (122)
 Other 58% (140)
Medications
 Diuretics 49% (118)
 ACE inhibitors or A-II receptor blockers 70% (167)
 Beta blocker 50% (119)
 Calcium channel blocker 42% (101)
 Erythropoiesis-stimulating agent 24% (57)
 Statin 45% (108)
Laboratory values
 C-reactive protein (mg/L) 1.7 (0, 50)
 Intact parathyroid hormone (ng/mL) 111 (5, 991)
 Estimated GFR (mL/min/1.73m2) 29 (12)
 Serum creatinine (mg/dL) 2.2 (1, 11)
 Serum albumin (g/dL) 4.0 (0.5)
 Blood urea nitrogen (mg/dL) 38 (14, 131)
 Corrected serum calcium (mg/dL) 9.2 (0.6)
 Serum glucose (mg/dL) 97 (46, 393)
 Serum phosphorus (mg/dL) 3.7 (0.9)
 Serum potassium (mEq/L) 4.5 (0.6)
 Hemoglobin (g/dL) 12.1 (1.6)
 Urine albumin/creatinine ratio 191 (2, 9259)
an = 239 for BMI, albumin, and calcium; 238 ≤ n ≤ 234 for phosphorus, iPTH, 
BUN, cholesterol, and potassium; 230 ≤ n ≤ 228 for Alb/Cr ratio, glucose, and 
CRP; and n = 219 for HG. bMultiple causes of CKD are possible.
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univariate analysis and/or factors known 
to affect PWV. The method of best subsets 
with the R-squared selection criterion guided 
the model selection process [19]. HRV pa-
rameters were then added one at a time to 
this multivariable linear regression model 
to assess the independent effect of HRV on 
PWV. However, since several of the clinical 
variables included in this model were also 
significantly correlated with HRV, the HRV-
PWV association was further explored by 
examining regression models with increas-
ing adjustment for the significant predictors 
of PWV in multivariable analyses. Cox re-
gression was used to analyze time-to-event 
outcomes. All variables from Table 1 were 
included to determine the clinical predictors 
of the composite outcome of CVD/Death 
and ESRD, and the method of best subsets 
with the likelihood score (chi-square) statis-
tic selection criterion was used to guide mod-
el selection. These models are referred to as 
“base” models for each outcome (Table S5). 
Each measure of HRV and PWV were then 
added to this “base” model to assess their in-
dependent associations with each outcome. 
Models with and without medications were 
tested, however, final models were selected 
without medications; this did not signifi-
cantly affect the results. Skewed variables 
were natural log transformed and a p-value 
< 0.05 was considered significant. All analy-
ses were conducted using SAS, version 9.2 
(SAS Institute Inc., Cary, NC, USA).
A previous publication yielded similar 
outcomes for using 24-hour, night and day 
HRV measures [11]; for the purpose of this 
manuscript, we only present 24-hour HRV 
measures for analysis Furthermore, only 
those 24-h HRV measures that were sig-
nificantly associated with PWV (LF, LF/HF, 
VLF, TP, ASDNN) in univariate analyses 
were further explored in subsequent regres-
sion models and survival analysis. Pearson 
correlations among these selected 24-hour 
HRV measures in this CKD cohort are re-
ported in Table S2.
Results
Baseline patient characteristics at the 
time of non-invasive cardiovascular testing 
are displayed in Table 1. The average age 
was 60 ± 15 years, 53% were male, 78% 
white, and 18% black. A majority were hy-
pertensive (89%), 30% were diabetic, 35% 
had a history of CVD, and 47% were smok-
ers. Table 2 shows baseline measurements of 
HRV and PWV overall and by presence or 
Table 2. Pulse wave velocity (PWV) and heart rate variability (HRV) measurements at the time of non-
invasive cardiovascular testing in the RRI-chronic kidney disease (CKD) cohort. Continuous variables 
are reported as mean (standard deviation) for normally distributed variables and as median (min, max) 
for skewed variables. Categorical variables are reported as % (n). Significant differences between those 







Pulse wave velocity (m/s) 8.6 (2.8) 10.3 (3.2) 7.9 (2.3)
HRV time domain (ms)
 Standard deviation (SD) of all 
 normal to normal R-R (NN) intervals
105 (36,306) 92 (36, 306) 108 (48, 227)
 SD of 5-min average NN intervals 
 (SDANN)
89 (25,258) 78 (25, 258) 93 (39, 199)
 Average 5-minute SDNN over 24 h 
 (ASDNN)
41 (17,195) 36 (17, 188) 44 (18, 195)
 Root mean square of the difference 
 of successive RR intervals (RMSSD)
24 (6, 267) 27 (6, 267) 23 (8, 260)
HRV frequency domain (ms2)
 Total power 1,554 (256, 30828) 1,131 (256, 25058) 1,687 (297, 30828)
 Very low frequency (VLF) 1,014 (36, 6252) 690 (36, 5908) 1,139 (101, 6252)
 Low frequency (LF) 310 (13, 11977) 177 (13, 6688) 349 (24, 11977)
 High frequency (HF) 120 (5, 15123) 97 (5, 11247) 128 (11, 15123)
 Low/high frequency ratio (LF/HF) 2.5 (0.2, 14) 1.8 (0.3, 9.0) 2.9 (0.2, 13.9)
aHRV frequency domain measures, n = 239 overall, n = 71 for diabetics.
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absence of diabetes. These comparisons were 
made to validate the known link between di-
abetes and both autonomic dysfunction and 
increased vascular stiffness (i.e., low HRV 
and high PWV respectively) [8, 11]. In this 
CKD cohort, PWV was significantly higher 
and most HRV measures were significantly 
lower in diabetics than in non-diabetics.
Associations of PWV with  
baseline clinical characteristics 
and HRV
Table S3 displays univariate associations 
of patient characteristics with PWV. Several 
clinically important variables such as older 
age, diabetes (DM), hypertension, history of 
CVD, higher values of: systolic blood pres-
sure (SBP), heart rate (HR; p = 0.056), body 
mass index (BMI), corrected serum calcium, 
fasting blood glucose, or C-reactive protein 
(CRP), and use of diuretics or calcium chan-
nel blockers were all significantly associ-
ated with higher PWV. No association was 
observed between total cholesterol, LDL, 
HDL or triglycerides, serum phosphorus, al-
bumin, hemoglobin, eGFR, smoking, use of 
beta-blockers or ACE/ARB with PWV. Sev-
eral time and frequency domain measures 
of HRV (LF, VLF, LF/HF ratio, total power 
(TP) and ASDNN) were inversely correlated 
with PWV and with low HRV associated 
with high PWV (Figure 2) (Table 4).
In multivariable analyses, older age, 
higher SBP, higher HR, DM, higher BMI, 
and elevated CRP were significantly asso-
ciated with high PWV (Table 3). After si-
multaneous adjustment for these variables, 
PWV was no longer significantly associated 
with HRV. However, since several of these 
variables were also associated with HRV in 
this cohort (Table 4), the association of HRV 
and PWV with increasing adjustment for 
these variables was also explored (Table S4). 
Model 1 displays the significant unadjusted 
inverse HRV-PWV association. Models 2a – 
2d show a slight attenuation of this associa-
Table 3. Multivariable linear regression models predicting pulse wave velocity in the RRI-chronic kidney 
disease (CKD) cohort.
Model 1 Model 2
n = 239 R2 = 0.46 n = 228 R2 = 0.46
Variable β p-value Variable β p-value
Age 0.07 < 0.0001 Age 0.07 < 0.0001
Diabetes 1.46 < 0.0001 Diabetes 1.70 < 0.0001
Systolic blood pressurea 
(mm/Hg)
0.03 < 0.0001 Systolic blood pressurea 
(mm/Hg)
0.03 < 0.0001
Heart rate (bpm) 0.03 0.0059 Heart rate (bpm) 0.03 0.0398
Body mass index (kg/m2) 0.06 0.0068 C-reactive protein (mg/L) 0.29 0.0394
aSubstitution of mean arterial pressure for systolic blood pressure yielded similar results.
Figure 2. Scatter plot and least squares regression line for pulse wave velocity (PWV) versus (A) very low 
frequency and (B) average of 5-minute standard deviation of all normal to normal R-R intervals over 24 
hours (ASDNN).
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tion after adjustment for age, DM, CRP, or 
HR. The addition of either SBP (Model 3b) 
or BMI (Model 3c), or both (Model 4b) to 
the age-adjusted model did not significantly 
alter the age-adjusted HRV-PWV associa-
tion. Although the addition of diabetes did 
further attenuate the magnitude of the age-
adjusted HRV-PWV association (Model 3a), 
ASDNN and TP remained significantly asso-
ciated with PWV. However, the relationship 
between HRV and PWV is no longer signifi-
cant with the addition of either HR (Model 
3d) or CRP (Model 3e) to the age-adjusted 
model or age and diabetes adjusted model 
(Model 4d, e).
Association of PWV and HRV 
with clinical outcomes
In this cohort, 37 patients had at least one 
CVD event, 9 patients died, and 53 reached 
ESRD.
Table 4. Pearson correlations of selected 24-hour HRV measures (log-scale) with significant predictors of PWV (and with PWV) in 
this CKD cohort.
 Age Diabetes Systolic blood 
pressure






HRV measure (over 24 h) (years)  (mm/Hg) (bpm) (kg/m2) (mg/L) (m/s)
Time domain (ms)
 SD of 5-min average 
 NN intervals (SDANN)
r  =  –0.02 r  =  –0.19** r  =  –0.05 r  =  –0.35*** r  =  –0.08 r  =  –0.24*** r  =  –0.14*
 Average 5-minute SDNN 
 (ASDNN)
r  =  –0.03 r  =  –0.14* r  =  –0.06 r  =  –0.32*** r = –0.02 r = –0.23*** r = –0.16*
Frequency domain (ms2)
 Total power r = –0.03 r = –0.19** r = –0.06 r = –0.33*** r = –0.03 r = –0.24*** r = –0.18*
 Very low frequency (VLF)  r = –0.15* r = –0.28*** r = –0.04 r = –0.42*** r = –0.06 r = –0.23*** r = –0.29***
 Low frequency (LF) r = –0.12 r = –0.24*** r = –0.12 r = –0.23*** r = –0.01 r = –0.21** r = –0.22***
 Low/high frequency ratio 
 LF/HF)
  r = –0.32*** r = –0.27***  r = –0.18* r = –0.11 r = –0.12 r = –0.12 r = 0.26***
*p < 0.05, **p < 0.005, ***p < 0.0005.
Table 5. Adjusted Cox regression models predicting time to (A) composite of first cardiovascular disease (CVD) events or death and 
(B) ESRD endpoints. Starting with a base model for each endpoint (Table S5), either pulse wave velocity (PWV) or measure of heart 
rate variability (HRV; log-scale) was separately added to the base model (I) and then simultaneously added to the base model (II). 
Significant associations (p < 0.05) are in bold and marginal associations (p < 0.10) are shaded.
 I. Base modela,b + PWV or HRV II. Base modela,b + PWV + HRV
 Hazard ratio for 
PWV/HRV








(A) First CVD event or death 
 PWV (m/s) 1.19 (1.09,1.31) 0.0002
 ASDNN (ln ms) 0.39 (0.18,0.83) 0.0145 0.46 (0.22,0.97) 0.0400 1.17 (1.07,1.28) 0.0006
 Total power (ln ms2) 0.60 (0.40,0.89) 0.0103 0.66 (0.45,0.97) 0.0355 1.17 (1.07,1.28) 0.0008
 VLF (ln ms2) 0.57 (0.41,0.79) 0.0009 0.69 (0.49,0.97) 0.0304 1.14 (1.03,1.25) 0.0089
 Low frequency (ln ms2) 0.60 (0.45,0.80) 0.0005 0.65 (0.49,0.86) 0.0025 1.16 (1.06,1.27) 0.0010
 LF/HF ratio 0.50 (0.35,0.71) < 0.0001 0.53 (0.37,0.77) 0.0007 1.15 (1.05,1.26) 0.0019
(B) ESRD
 PWV (m/s) 1.01 (0.91,1.12) 0.7934
 ASDNN (ln ms) 0.64 (0.33,1.23) 0.1810 0.63 (0.32,1.26) 0.1915 1.00 (0.90,1.11) 0.9521
 Total power (ln ms2) 0.77 (0.55,1.09) 0.1399 0.77 (0.54,1.10) 0.1473 0.99 (0.89,1.11) 0.8875
 VLF (ln ms2) 0.66 (0.47,0.93) 0.0191 0.62 (0.41,0.92) 0.0168 0.96 (0.85,1.07) 0.4391
 Low frequency (ln ms2) 0.84 (0.65,1.07) 0.1563 0.83 (0.65,1.08) 0.1646 1.00 (0.90,1.11) 0.9482
 LF/HF ratio 0.93 (0.64,1.36) 0.7167 0.94 (0.63,1.41) 0.7704 1.01 (0.90,1.12) 0.8830
ASDNN = Average 5-minute SDNN over 24 hours; VLF = very low frequency; LF/HF ratio = low/high frequency ratio.
aFirst CVD event or death: adjusted for h/o CVD, gender, and serum albumin (n = 238, 46 events, R2 = 0.11).
bESRD: adjusted for eGFR, ln(ipth), and ln (Alb/CR) (n = 226, 51 events, R2 = 0.37).
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In unadjusted analyses, both high PWV 
and low HRV were associated with increased 
risk of CVD. In multivariable analyses, the 
risk of the composite outcome of first CVD 
event or death was higher in males, those 
with prior history of CVD and with low se-
rum albumin. (Table 5). After adjusting for 
these variables, low HRV and high PWV 
were each significantly associated with high-
er risk of CVD/death (Table 5(A)).
Increased risk of ESRD was associated 
with lower baseline eGFR, higher urine al-
bumin to creatinine ratio, and higher iPTH in 
multivariable analysis (Table 5). PWV was 
not associated with risk of ESRD whereas 
amongst HRV measures, only VLF was sig-
nificant (Table 5 (B)).
When both HRV and PWV are placed 
together in the model predicting CVD/death, 
both HRV and PWV are associated with in-
creased risk of CVD/death (Table 5 (A)). 
As shown in Figure 3, patients with either 
a low LF/HF ratio and/or high PWV were 
associated with a higher risk of CVD/death 
compared to patients with both a high LF/HF 
ratio and low PWV. The risk of CVD/death 
was highest among patients with both a low 
LF/HF and a high PWV. Similar findings 
were observed with other HRV measures 
(LF, VLF, ASDNN, and total power-data not 
shown).
Discussion
CKD has been linked with both increased 
sympathetic activity as well as higher arterial 
stiffness, both of which are associated with 
adverse cardiovascular outcomes and mor-
tality in this population [2, 3, 4, 5, 6, 7, 9, 10, 
11]. We undertook this analysis to (i) explore 
the relationship between autonomic dysfunc-
tion (as assessed by HRV) and arterial stiff-
Figure 3. The cumulative probability of first cardiovascular disease (CVD) 
event or death over time since Holter monitoring by higher or lower (above/below 
median) PWV and HRV (median PWV = 8.35 m/s; median Ln(LF/HF) ratio = 1.26 
ms2). Plotted values were calculated based on Cox regression adjusted for 
mean values of: age (60 years), phosphorus (3.7), albumin (4.0), proportion with 
history of CVD (0.35), and proportion male (0.53).
Table S1. Overview of heart rate variability parameters.
Frequency domain HRV 
measures
Unit Description
VLF Power in very low 
frequency range
ms2 Physiological correlate unclear; 
may reflect vasomotor function, 
renin angiotensin system, and/or 
parasympathetic influence
LF Power in low 
frequency range
ms2 Reflects sympathetic or sympa-
thetic parasympathetic influence.
LF/HF Ratio of low to high 
frequency power
– Reflects sympathovagal balance.
TP Total power ms2 Estimate of overall HRV.
Time domain HRV measures Unit Description
ASDNN Average of all 
5-minute SDNN 
over 24
ms Estimate of short-term components 
of HRV (i.e., changes in heart rate 
due to cycles < 5 minutes).
References:
[10] Heart Rate Variability. Standards of measurement, physiological interpre-
tation and clinical use, Task Force of European Society of Cardiology and the 
North American society of pacing and electrophysiology. Eur Heart J. 1996; 17: 
354-381.
Kleiger RE, Stein PK, Bigger JT. Heart Rate Variability: Measurement and 
Clinical Utility. Ann Noninvasive Electrocariol. 2005; 10: 88-101. PubMed
Table S2. Pearson correlations among selected 24-h HRV measures (log-scale) in this CKD cohort.










ASDNN (ms) –  0.96** 0.81** 0.92** –0.03
Total power (ln ms2)  0.96** – 0.83** 0.91**  0.04
VLF (ln ms2)  0.81**  0.83** – 0.77**  0.25**
Low frequency (ln ms2)  0.92**  0.91** 0.77** –  0.14*
LF/HF ratio (ms2) –0.03 0.04 0.25** 0.14* –
*p < 0.05, **p < 0.0005.
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ness (as measured by PWV) in a CKD cohort 
and (ii) to assess the association of both HRV 
and PWV (individually and combined) on 
patient outcomes.
We had postulated that we would find an 
inverse relationship between PWV and HRV 
among patients with CKD, consistent with 
prior experimental evidence outlined below. 
We found that HRV was indeed significantly 
inversely correlated with PWV in unadjusted 
analyses. However, after progressively ad-
justing for confounders, particularly CRP 
and HR, this association was no longer sig-
nificant (Table S4). Heart rate is an important 
influence on PWV [20], and heart rate is inti-
mately linked with HRV. Similarly, CRP has 
been associated with low HRV in this patient 
cohort [11]. CRP was also associated with 
higher PWV in this cohort, consistent with 
prior literature [21]. In addition, CRP was 
inversely related to heart rate in this cohort 
(R = 0.31, < 0.0001). Hence, heart rate and 
CRP are important confounders in the HRV-
PWV relationship. In prior work, HRV has 
been associated with arterial stiffness in both 
type 1 and type 2 diabetics although these 
analyses were not adjusted for heart rate [12, 
13, 14], while a study by Ittersum et al. [15] 
showed that aortic PWV was associated with 
mean autonomic score adjusted for age, BP, 
and heart rate.
The relationship between autonomic ner-
vous system and arterial stiffness, however, 
remains plausible. Increased sympathetic 
activity with resultant increased heart rate 
can cause damage to elastin fibers resulting 
in replacement with collagen and resultant 
decreased elasticity and compliance. In di-
rect support of a causal relationship between 
activation of the sympathetic nervous system 
and abnormalities in fibrosis/loss of arterial 
compliance, sympathectomy in rats results 
in increased distensibility (and hence more 
compliance) in both muscular arteries, such 
as femoral as well as larger elastic arter-
ies, such as carotid artery. This increase in 
distensibility was independent of decrease 
in blood pressure resulting from sympa-
thectomy [22]. The same authors have also 
suggested that in the larger elastic carotid 
arteries in rats, reduced distensibility from 
pacing induced tachycardia is likely more 
related to the viscous properties of the ves-
sel wall and inertial response to intravascu-
lar pressure than to the smooth muscle tone 
[23]. In a study by Sa Cunha et al. [24], high 
PWV was associated with higher heart rate 
and lower baroreceptor sensitivity after ad-
justment for age and systolic BP in patients 
with hypertension. Fatigue and fracture of 
the elastic fibers in the arterial wall are the 
major causes of increased arterial stiffness 
with aging; this alteration is more prominent 
in the larger “elastic” arteries that pulsate to 
Table S3. Univariate associations of patient characteristics with pulse wave 




Age  0.09 < 0.0001
Gender: male –0.29  0.3752
Race: white  0.33  0.4019
Body mass index (kg/m2)  0.09  0.0013
Current/former smoker –0.41  0.4362
Cardiovascular indices
 Systolic blood pressure (mm/Hg) 0.05 < 0.0001
 Diastolic blood pressure (mm/Hg) –0.003  0.8008
 Heart rate (bpm) 0.03  0.0568
Comorbidities
 Diabetes 2.45 < 0.0001
 Hypertension 0.97  0.0438
 Cardiovascular disease 1.29  0.0002
Medications
 Diuretics  0.92 0.0041
 ACE Inhibitors or A-II receptor Blockers –0.50 0.1471
 Beta blocker  0.27 0.3999
 Calcium channel blocker  0.91 0.0052
 Erythropoiesis-stimulating agent –0.13 0.7329
 Statin –0.16 0.6156
Laboratory values
 C-Reactive protein (mg/L) 0.46 0.0100
 Intact parathyroid hormone (ng/mL) 0.08 0.6748
 Estimated GFR (mL/min/1.73m2) –0.004 0.7591
 Serum creatinine (mg/dL) –0.58 0.1406
 Serum albumin (g/dL) –0.46 0.1853
 Blood urea nitrogen (mg/dL)  0.22 0.5668
 Corrected serum calcium (mg/dL)  0.60 0.0265
 Serum glucose (mg/dL)  2.29 0.0008
 Serum phosphorus (mg/dL) 0.002 0.9924
 Serum potassium (meq/L) –0.06 0.8203
 Hemoglobin (g/dL) –0.08 0.4433
 Total cholesterol (mg/dL)  0.01 0.0993
 Low density lipoprotein (mg/dL)  0.01 0.1462
 High density lipoprotein (mg/dL) –0.003 0.8035
 Triglycerides (mg/dL)  0.19 0.5154
 Urine albumin/creatinine ratio  0.02 0.8203
an = 239 for BMI, albumin, and calcium; 238 ≤ n ≤ 234 for phosphorus, iPTH, 
BUN, cholesterol, and potassium; 230 ≤ n ≤ 228 for Alb/Cr ratio, glucose, and 
CRP; and n = 219 for HG.
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a greater degree than the “muscular” arteries 
like the femoral [25]. There is experimental 
evidence that cyclic stretching stimulates 
production of increased matrix proteins by 
aortic smooth muscle cells in vitro [22], and 
that increased hemodynamic stress (product 
of heart rate and BP) is associated with in-
creased aortoiliac atherosclerosis in experi-
mental animals [26].
In this CKD cohort, higher PWV was as-
sociated with greater risk of the composite 
outcome of first CVD event or death in multi-
variable analysis. This is consistent with prior 
studies from different populations including 
ESRD [1, 2, 3, 4] and underscores the impor-
tance of arterial stiffness as an adverse prog-
nostic indicator. HRV measures (LF, LF/HF, 
VLF, TP, and ASDNN) were also associated 
with CVD/death risk in this cohort as previ-
ously reported [11]. When both PWV and 
any of these HRV measures are placed in the 
same model predicting the risk of CVD/death, 
PWV and HRV are independently associated 
with these outcomes, with the highest risk ob-
served among patients with both a low HRV 
and a high PWV. These findings suggest con-
sideration of both arterial stiffness and HRV 
together provide a greater prognostic signifi-
cance compared to consideration of either 
measure alone. Data from larger cohorts with 
both measurements would be desirable to fur-
ther substantiate these findings.
While one measure of HRV (namely 
VLF) was associated with increased risk for 
ESRD, an association between PWV and risk 
to ESRD was not observed in this cohort. A 
weak association between HRV and ESRD 
Table S4. Models display the association between pulse wave velocity (PWV) and heart rate variability (HRV; log-scale) with increas-
ing adjustment for significant predictors of PWV in multivariable analyses (age, heart rate (HR)), C-reactive protein (CRP), diabetes 
(DM), and body mass index (BMI). Model estimates (β) and p-values from each model are reported. Significant associations are in 
bold (p < 0.05).
 Y = PWV (1) Unadjusted (2a) Age-Adjusted (2b) DM-Adjusted (2c) HR-Adjusted (2d) CRP-Adjusted
HRV Measure b p-value b p-value b p-value b p-value b p-value
ASDNN (ms) –1.20 0.0026 –0.81 0.0196 –0.91 0.0167 –1.07 0.0119 –0.79 0.0629
Total power (ms2) –0.63 0.0024 –0.44 0.0142 –0.46 0.0210 –0.56 0.0108 –0.44 0.0487
VLF (ms2) –0.81 0.0001 –0.46 0.0098 –0.61 0.0023 –0.58 0.0003 –0.68 0.0025
Low frequency (ms2) –0.62 0.0001 –0.34 0.0131 –0.46 0.0026 –0.78 0.0005 –0.48 0.0043
LF/HF ratio (ms2) –0.78 0.0003 –0.23 0.2444 –0.56 0.0088 –0.76 0.0005 –0.61 0.0048
2-Variable models: (3a) Age + DM (3b) Age + SBP (3c) Age + BMI (3d) Age + HR (3e) Age + CRPa
b p-value b p-value b p-value b p-value b p-value
ASDNN (ms) –0.66 0.0470 –0.78 0.0146 –0.81 0.0177 –0.53 0.1439 –0.53 0.1538
Total power (ms2) –0.34 0.0489 –0.41 0.0123 –0.45 0.0117 –0.30 0.1083 –0.32 0.0880
VLF (ms2) –0.33 0.0618 –0.47 0.0048 –0.45 0.0102 –0.31 0.1134 –0.32 0.0889
Low frequency (ms2) –0.24 0.0702 –0.29 0.0232 –0.36 0.0088 –0.27 0.0603 –0.23 0.1104
LF/HF ratio (ms2) –0.06 0.7705 –0.09 0.6198 –0.19 0.3322 –0.18 0.3694 –0.19 0.3421
3-Variable models: (4a) Age + DM + 
SBP
(4b) Age + SBP + 
BMI
(4c) Age + BMI + 
DM
(4d) Age + HR + 
DM
(4e) Age + CRP + 
DM
b p-value b p-value b p-value b p-value b p-value
ASDNN (ms) –0.65 0.0357 –0.79 0.0116 –0.66 0.0433 –0.44 0.2055 –0.39 0.2631
Total power (ms2) –0.33 0.0401 –0.42 0.0090 –0.35 0.0428 –0.23 0.2078 –0.23 0.2065
VLF (ms2) –0.35 0.0315 –0.46 0.0047 –0.32 0.0613 –0.19 0.3149 –0.18 0.3188
Low frequency (ms2) –0.21 0.0934 –0.31 0.0142 –0.26 0.0524 –0.18 0.1908 –0.13 0.3437
LF/HF ratio (ms2) 0.04 0.8262 –0.05 0.7883 –0.04 0.8454 –0.01 0.9455 –0.02 0.9365
ASDNN = Average 5-minute SDNN over 24 hours, VLF = very low frequency, LF/HF ratio = low/high frequency ratio.
Table S5. Multivariable Cox regression models predicting time to (A). Com-
posite of first cardiovascular disease (CVD) event or death and (B) ESRD end-
points.
Base mdel HR (95% CI) p-value
 (A) First CVD event or death (46 events) n = 238, R2 = 0.09
History of CVD 2.69 (1.50,4.84) 0.0009
Males 1.83 (0.99,3.38) 0.0542
Albumin (g/dL) 2.69 (1.50,4.84) 0.0009
(B) ESRD endpoint (47 events) n = 226, R2 = 0.37
Estimated GFR (mL/min/1.73m2) 0.85 (0.81,0.89) <0.0001
Urine albumin/creatinine ratioa 1.33 (1.12,1.58) 0.0013
Intact parathyroid hormone (ng/mL)a 1.44 (1.03,2.02) 0.0344
aNatural log scale.
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in a larger sample from this cohort was also 
reported in a previous publication [11]. It is 
not clear why PWV was not associated with 
ESRD in this CKD cohort. We could specu-
late that there is a relationship, but this study 
has failed to uncover it because of a relative-
ly small sample size and/or short duration of 
follow-up. However, the latter possibility is 
less likely, given that there were a sizable 
number of ESRD events in this cohort; how-
ever, a previous publication discusses the 
lack of association between PWV and eGFR 
in this cohort [8].
This study has several strengths. The 
associations were studied in a fairly large 
number of CKD patients followed longi-
tudinally, with near simultaneous baseline 
measurements of arterial stiffness and heart 
rate variability, allowing us to investigate the 
integrated influence of these parameters in 
the same analysis, along with their potential 
associations. To the best of our knowledge, 
there are no other studies in the CKD litera-
ture looking at these parameters simultane-
ously with respect to their combined asso-
ciation with outcomes. Furthermore, arterial 
stiffness was measured at the aorta by a stan-
dardized technique that has been validated 
in previous studies. HRV was measured by 
a 24-hour Holter, which remains the gold 
standard. Availability of demographic and 
important baseline clinical data allowed us 
to perform multivariable analyses.
Certain limitations of this study need to 
be acknowledged. As with any observational 
study, we can only comment on associations 
and not causality. The outcomes, while sys-
tematically collected by study coordinators, 
were not adjudicated by committee. The 
number of deaths was small in this referred 
CKD clinic-based cohort; we therefore stud-
ied the composite outcome of CVD or death. 
Direct measurements of sympathetic activity 
were not part of the original study design. 
However, based on the published literature, 
heart rate variability is well-recognized as a 
surrogate of autonomic imbalance.
Summary and conclusion
This study describes association between 
autonomic dysfunction as measured by HRV 
and arterial stiffness as measured by PWV in 
a multicenter prospective CKD cohort. HRV 
appears to be inversely correlated with PWV. 
However, this correlation was explained by 
age, presence of diabetes, and CRP levels, 
suggesting that underlying inflammation 
may well be an important confounder of this 
relationship and may mediate abnormali-
ties in both parameters. Both low HRV and 
high PWV were associated with higher risk, 
the composite of CVD/death in this cohort, 
with the risk of CVD/death being highest in 
those patients with a combination of both a 
low HRV and a high PWV. Future research 
should further examine these associations in 
larger cohorts and clarify underlying mecha-
nisms in patients with CKD with the aim of 
identifying populations at greatest risk for 
adverse CVD events. Both HRV and PWV 
could be considered for investigation as po-
tential intermediate outcome measures in fu-
ture clinical trials for this high risk patient 
population.
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